

Eiger BioPharmaceuticals to Participate in Investor Conferences

PALO ALTO, Calif., August 27, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that members of the Eiger management team will participate in multiple investor conferences in September in New York City.

Details of September Investor Conferences:

- *B. Riley FBR Healthcare Conference, September 4, 2018 at the Marriott New York Eastside Hotel. Panel: “Hepatitis B Functional Cure Cannot Be Improved”, 9:50 - 10:50 AM ET, Stuyvesant Room. Eiger will host one-on-one meetings.*
- *H.C. Wainwright 20th Annual Global Investment Conference at the St. Regis Hotel, New York City. Corporate Presentation September 6, 2018, 5:05 PM ET. Eiger will host one-on-one meetings.*
- *BioCentury NewsMakers in the Biotech Industry Conference at the Millenium Broadway Hotel & Conference Center, New York City. Corporate Presentation September 7, 2018, 1:30 PM ET. Eiger will host one-on-one meetings.*

A live webcast of the September 6th H.C. Wainwright presentation will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com under the “Investors” tab. A replay of the webcast will be available approximately one hour following the completion of the live event.

About Eiger

Eiger is a late stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases. We innovate by developing well-characterized drugs in newly identified or novel targets in rare diseases. Our mission is to systematically reduce the time and cost of the drug development process to more rapidly deliver important medicines to patients. Our lead program in Hepatitis Delta Virus (HDV) infection is advancing into Phase 3 with a single, pivotal trial (D-LIVR Study) planned to initiate by the end of 2018. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.



SOURCE Eiger BioPharmaceuticals, Inc.

Investors: Ingrid Choong, PhD

Email: ichoong@eigerbio.com / Phone: 1-650-619-6115